Research Article

*Author for correspondence: Tel.: +90 506 313 6650;

Ankara Bilkent City Hospital, Clinic of Rheumatology, Ankara, 06800, Turkey

Department of Internal Medicine, Ankara Yıldırım Beyazıt University Medical School, Division of Rheumatology, Ankara, 06800, Turkey

Search for more papers by this author

Serdar Can Güven

https://orcid.org/0000-0003-1965-9756

Ankara Bilkent City Hospital, Clinic of Rheumatology, Ankara, 06800, Turkey

Search for more papers by this author

Berkan Armağan

https://orcid.org/0000-0003-4409-059X

Ankara Bilkent City Hospital, Clinic of Rheumatology, Ankara, 06800, Turkey

Search for more papers by this author

Öykü Tayfur Yürekli

Department of Internal Medicine, Ankara Yıldırım Beyazıt University Medical School, Division of Gastroenterology, Ankara, 06800, Turkey

Search for more papers by this author

Yasemin Özderin Özin

Department of Internal Medicine, Health Sciences University Medical School, Ankara Bilkent City Hospital, Division of Gastroenterology, Ankara, 06800, Turkey

Search for more papers by this author

Ahmet Omma

Department of Internal Medicine, Health Sciences University Medical School, Ankara Bilkent City Hospital, Division of Rheumatology, Ankara, 06800, Turkey

Search for more papers by this author

Orhan Küçükşahin

Department of Internal Medicine, Ankara Yıldırım Beyazıt University Medical School, Division of Rheumatology, Ankara, 06800, Turkey

Search for more papers by this author

Published Online:5 Apr 2023https://doi.org/10.2217/imt-2022-0197

View article

Abstract

Objective: The aim of this study was to evaluate the efficacy of ustekinumab in the treatment of enteropathic arthritis. Materials & methods: A systematic literature search was performed in the Pubmed database of publications between January 2010 and October 2021. Demographic characteristics, comorbidities, inflammatory bowel disease and enteropathic arthritis symptoms, other extraintestinal findings, medical treatments and clinical and laboratory findings for all cases were recorded. Results: A total of 11 patients were included. While clinical and laboratory remission was achieved in terms of inflammatory bowel disease in all patients and enteropathic arthritis in nine patients after ustekinumab treatment, other extraintestinal findings for all patients completely regressed after treatment. Conclusion: Ustekinumab may be an appropriate treatment option for this patient group, considering both pathogenesis and successful treatment responses.

Plain language summary

Treatments targeting the IL-23 pathway are highly effective in psoriasis, psoriatic arthritis and inflammatory bowel diseases. However, their efficacy in patients with enteropathic arthritis with peripheral and/or axial joint involvement is unclear. Ustekinumab may be a valuable option for patients who cannot adhere to other treatment options due to side effects or ineffectiveness. Considering its positive effects on joint involvement in patients with psoriatic arthritis, the current work was designed to investigate the efficacy of ustekinumab in patients with enteropathic arthritis on both gut and extraintestinal involvement, particularly musculoskeletal symptoms.

Tweetable abstract

Ustekinumab is a biological agent blocking the IL-12/23 pathway. Considering its effectiveness in psoriatic arthritis and inflammatory bowel disease, it may also be an option for enteropathic arthritis.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Holden W, Orchard T, Wordsworth P. Enteropathic arthritis. Rheum. Dis. Clin. North Am. 29(3), 513–530 (2003).
MedlineGoogle Scholar
2. Colìa R, Corrado A, Cantatore FP. Rheumatologic and extraintestinal manifestations of inflammatory bowel diseases. Ann. Med. 48(8), 577–585 (2016).
Medline CASGoogle Scholar
3. Salvarani C, Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J. Gastroenterol. 15(20), 2449–2455 (2009).
MedlineGoogle Scholar
4. Jacques P, Elewaut D, Mielants H. Interactions between gut inflammation and arthritis/spondylitis. Curr. Opin. Rheumatol. 22(4), 368–374 (2010).
MedlineGoogle Scholar
5. Van Praet L, Van den Bosch F, Mielants H, Elewaut D. Mucosal inflammation in spondylarthritides: past, present, and future. Curr. Rheumatol. Rep. 13(5), 409–415 (2011).
MedlineGoogle Scholar
6. Peluso R, Di Minno MND, Iervolino S et al. Enteropathic spondyloarthritis: from diagnosis to treatment. Clin. Dev. Immunol. 2013, 631408 (2013).
MedlineGoogle Scholar
7. Neurath MF. IL-23 in inflammatory bowel diseases and colon cancer. Cytokine Growth Factor Rev. 45, 1–8 (2019).
Medline CASGoogle Scholar
8. Biancone L, Tosti C, Fina D et al. Review article: maintenance treatment of Crohn's disease. Aliment. Pharmacol. Ther. 17(Suppl. 2), 31–37 (2003).
Medline CASGoogle Scholar
9. Jilani NZ, Akobeng AK. Selected summary. J. Pediatr. Gastroenterol. Nutr. 46(2), 226–227 (2008).
MedlineGoogle Scholar
10. Mcinnes IB, Kavanaugh A, Gottlieb AB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382(9894), 780–789 (2013).
Medline CASGoogle Scholar
11. Feagan BG, Sandborn WJ, Gasink C et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 375(20), 1946–1960 (2016). • Clinical research demonstrating the efficacy and safety of ustekinumab in Crohn's disease.
Medline CASGoogle Scholar
12. Sands BE, Sandborn WJ, Panaccione R et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 381(13), 1201–1214 (2019). • Clinical research demonstrating the efficacy and safety of ustekinumab in ulcerative colitis.
Medline CASGoogle Scholar
13. Nerviani A, Boutet MA, Tan WSG et al. IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors. Ann. Rheum. Dis. 80(5), 591–597 (2021).
Medline CASGoogle Scholar
14. Fiechter RH, de Jong HM, van Mens LJJ et al. IL-12p40/IL-23p40 blockade with ustekinumab decreases the synovial inflammatory infiltrate through modulation of multiple signaling pathways including MAPK-ERK and Wnt. Front. Immunol. 12, 611656 (2021).
Medline CASGoogle Scholar
15. Urushikubo J, Kawasaki K, Eizuka M et al. Ustekinumab improves paradoxical enteropathy associated with psoriasis arthritis. Inflamm. Bowel Dis. 25(10), e128–e129 (2019).
MedlineGoogle Scholar
16. Matsumoto S, Mashima H. Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn's disease. Biologics 12, 69–73 (2018).
MedlineGoogle Scholar
17. Matsumoto S, Matsumoto K, Takaya H, Otake H, Mashima H. Efficacy of ustekinumab against spondyloarthritis associated with Crohn's disease: a case report and review of the literature. Open Access Rheumatol. 12, 133–137 (2020).
MedlineGoogle Scholar
18. Cámara PG, Zubiri Ara ML, López SG. Ustekinumab in a patient with pyoderma gangrenosum and refractory Crohn's disease. Med. Clin. (Barc) 153(8), e35–e36 (2019).
MedlineGoogle Scholar
19. Chateau T, Peyrin-Biroulet L. Two cases of inflammatory bowel disease patients treated with ustekinumab 90 mg every 3 weeks. Inflamm. Bowel Dis. 26(2), e7 (2020).
MedlineGoogle Scholar
20. Taxonera C, Alba C, Colmenares M, Olivares D, Rey E. Recurrent granulomatous cheilitis associated with Crohn's disease successfully treated with ustekinumab: case report and literature review. Therap. Adv. Gastroenterol. 13, 1756284820934327 (2020).
Google Scholar
21. Machado PM, Landewé R, Heijde DV. Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann. Rheum. Dis. 77(10), 1539–1540 (2018).
MedlineGoogle Scholar
22. Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res. (Hoboken) 63(Suppl. 11), S47–S58 (2011).
MedlineGoogle Scholar
23. Teng MW, Bowman EP, Mcelwee JJ et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat. Med. 21(7), 719–729 (2015).
Medline CASGoogle Scholar
24. Schurich A, Raine C, Morris V, Ciurtin C. The role of IL-12/23 in T cell-related chronic inflammation: implications of immunodeficiency and therapeutic blockade. Rheumatology (Oxford) 57(2), 246–254 (2018).
Medline CASGoogle Scholar
25. Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13(5), 715–725 (2000).
Medline CASGoogle Scholar
26. Croxford AL, Mair F, Becher B. IL-23: one cytokine in control of autoimmunity. Eur. J. Immunol. 42(9), 2263–2273 (2012).
Medline CASGoogle Scholar
27. Kavanaugh A, Ritchlin C, Rahman P et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann. Rheum. Dis. 73(6), 1000–1006 (2014). •• Data showing the efficacy of ustekinumab on joint manifestations in psoriatic arthritis.
Medline CASGoogle Scholar
28. Chan JR, Blumenschein W, Murphy E et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J. Exp. Med. 203(12), 2577–2587 (2006).
Medline CASGoogle Scholar
29. Hong K, Chu A, Lúdvíksson BR, Berg EL, Ehrhardt RO. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J. Immunol. 162(12), 7480–7491 (1999).
Medline CASGoogle Scholar
30. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625), 1665–1674 (2008).
Medline CASGoogle Scholar
31. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625), 1675–1684 (2008).
Medline CASGoogle Scholar
32. Ritchlin C, Rahman P, Kavanaugh A et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann. Rheum. Dis. 73(6), 990–999 (2014).
Medline CASGoogle Scholar
33. Kavanaugh A, Puig L, Gottlieb AB et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann. Rheum. Dis. 75(11), 1984–1988 (2016).
Medline CASGoogle Scholar
34. Appel H, Maier R, Bleil J et al. In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum. 65(6), 1522–1529 (2013).
Medline CASGoogle Scholar
35. Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann. Rheum. Dis. 73(5), 817–823 (2014). •• Proof-of-concept study demonstrating efficacy and safety of ustekinumab in ankylosing spondylitis.
Medline CASGoogle Scholar
36. Deodhar A, Gensler LS, Sieper J et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 71(2), 258–270 (2019). •• Three placebo-controlled studies to evaluate efficacy and safety of ustekinumab in axial spondyloarthritis.
Medline CASGoogle Scholar
37. Wang K, Zhang H, Kugathasan S et al. Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn's disease. Am. J. Hum. Genet. 84(3), 399–405 (2009).
Medline CASGoogle Scholar
38. Strober W, Zhang F, Kitani A, Fuss I, Fichtner-Feigl S. Proinflammatory cytokines underlying the inflammation of Crohn's disease. Curr. Opin. Gastroenterol. 26(4), 310–317 (2010).
Medline CASGoogle Scholar
39. Sandborn WJ, Gasink C, Gao LL et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N. Engl. J. Med. 367(16), 1519–1528 (2012).
Medline CASGoogle Scholar
40. Sandborn WJ, Rebuck R, Wang Y et al. Five-year efficacy and safety of ustekinumab treatment in Crohn's disease: the IM-UNITI trial. Clin. Gastroenterol. Hepatol. 20(3), 578–590.e574 (2022).
Medline CASGoogle Scholar
41. Hanauer SB, Sandborn WJ, Feagan BG et al. IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's disease. J. Crohns Colitis 14(1), 23–32 (2020).
MedlineGoogle Scholar
42. D'haens G, Panaccione R, Baert F et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet 399(10340), 2015–2030 (2022).
MedlineGoogle Scholar
43. Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 376(18), 1723–1736 (2017).
Medline CASGoogle Scholar
44. Mugheddu C, Atzori L, Del Piano M et al. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis. Dermatol. Ther. 30(5), e12527 (2017).
Google Scholar
45. Salek SS, Pradeep A, Guly C, Ramanan AV, Rosenbaum JT. Uveitis and juvenile psoriatic arthritis or psoriasis. Am. J. Ophthalmol. 185, 68–74 (2018).
MedlineGoogle Scholar
46. Mao EJ, Lewin S, Terdiman JP, Beck K. Safety of dual biological therapy in Crohn's disease: a case series of vedolizumab in combination with other biologics. BMJ Open Gastroenterol. 5(1), e000243 (2018).
MedlineGoogle Scholar
47. Huff-Hardy K, Bedair M, Vazquez R, Burstein E. Efficacy of combination vedolizumab and ustekinumab for refractory Crohn's disease. Inflamm. Bowel Dis. 23(10), E49 (2017).
MedlineGoogle Scholar
48. Liu EY, Loomes DE. Ustekinumab and vedolizumab dual biologic therapy in the treatment of Crohn's disease. Case Rep. Med. 2017, 5264216 (2017).
MedlineGoogle Scholar

Vol. 15, No. 8

Metrics

Downloaded 129 times

History

Received 4 August 2022

Accepted 16 March 2023

Published online 5 April 2023

Published in print June 2023

Information

Keywords

Author contributions

B Özdemir Ulusoy, A Erden and SC Güven contributed to the acquisition and interpretation of study data. B Armağan, Ö Tayfur Yürekli, Y Özderin Özin, A Omma and O Küçükşahin contributed to the conception or design of the study and the acquisition, analysis and interpretation of study data. All authors drafted the work or revised it critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download

Ustekinumab in enteropathic arthritis

Abstract

Plain language summary

Tweetable abstract

References